Eisai在AD/PD 2026提交新的白血病数据,2026年5月24日前等待美国批准决定。 Eisai to present new lecanemab data at AD/PD 2026, with U.S. approval decision pending by May 24, 2026.

Eisai 将在 AD/PD™ 2026 会议上展示 lecanemab 的真实和长期新数据，包括治疗持久性、ApoEε4 携带者的安全性以及 Clarity AD 延期试验的四年结局。 Eisai will present new real-world and long-term data on lecanemab at the AD/PD™ 2026 conference, including treatment persistence, safety in ApoEε4 carriers, and four-year outcomes from the Clarity AD extension trial. 一项全基因组研究探讨了与认知下降的遗传联系,而一个专题讨论会则强调早期的、持续的治疗。 A genome-wide study explores genetic links to cognitive decline, while a symposium emphasizes early, sustained treatment. Lecanemab在53个国家获得批准,美国的补充应用正在优先审查中,预计将在2026年5月24日前作出决定。 Lecanemab, approved in 53 countries, has a U.S. supplemental application under priority review, with a decision expected by May 24, 2026.